Patient characteristics
| Patient characteristic, N = 72 . | . |
|---|---|
| Median age in years (range) | 40 (15-78) |
| Male, n (%) | 43 (60) |
| Median marrow blasts, % (range) | 89 (22-99) |
| Median WBC count, × 109/L (range) | 22.7 (0.9-669) |
| Median HgB in g/dL (range) | 9 (4.1-15.8) |
| Median Plt count, × 109/L (range) | 54.5 (10-449) |
| Cytogenetics, n (%) | |
| Diploid | 16 (22) |
| Hypodiploid | 2 (3) |
| Hyperdiploid | 4 (5) |
| Pseudodiploid | 8 (11) |
| t(9;22) | 18 (25) |
| t(v;11q23) | 0 (0) |
| t(12;21) | 0 (0) |
| t(1;19) | 2 (3) |
| Insufficient metaphases | 8 (11) |
| Others | 14 (19) |
| Immunophenotype,* n (%) | |
| Precursor T lymphoblastic | 8 (11) |
| Precursor B lymphoblastic | 64 (89) |
| Complete remission, n (%) | 66 (92) |
| Relapse, n (%) | 35 (48) |
| Median disease-free survival, wk | +100 |
| Median overall survival, wk | +137 |
| Patient characteristic, N = 72 . | . |
|---|---|
| Median age in years (range) | 40 (15-78) |
| Male, n (%) | 43 (60) |
| Median marrow blasts, % (range) | 89 (22-99) |
| Median WBC count, × 109/L (range) | 22.7 (0.9-669) |
| Median HgB in g/dL (range) | 9 (4.1-15.8) |
| Median Plt count, × 109/L (range) | 54.5 (10-449) |
| Cytogenetics, n (%) | |
| Diploid | 16 (22) |
| Hypodiploid | 2 (3) |
| Hyperdiploid | 4 (5) |
| Pseudodiploid | 8 (11) |
| t(9;22) | 18 (25) |
| t(v;11q23) | 0 (0) |
| t(12;21) | 0 (0) |
| t(1;19) | 2 (3) |
| Insufficient metaphases | 8 (11) |
| Others | 14 (19) |
| Immunophenotype,* n (%) | |
| Precursor T lymphoblastic | 8 (11) |
| Precursor B lymphoblastic | 64 (89) |
| Complete remission, n (%) | 66 (92) |
| Relapse, n (%) | 35 (48) |
| Median disease-free survival, wk | +100 |
| Median overall survival, wk | +137 |
WBC indicates white blood cell count; HgB, hemoglobin; Plt, platelet.
Immunophenotyping using the World Health Organization classification for tumors of hematopoietic origin.